Genzyme (GENZ) Reports Clolar(R) Data Further Supporting Potential of Product to Treat Adult AML Patients
Tweet Send to a Friend
Genzyme Corporation (Nasdaq: GENZ) reported preliminary data on secondary endpoints from its CLASSIC II investigational study examining the safety and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
